Cancer

Home to one of the nation’s leading early drug development programs, HonorHealth Research Institute offers more early phase cancer clinical trials than any other Arizona cancer center and is often the first site in the nation to evaluate a promising new therapy in a Phase I clinical trial.

In 2019, our researchers studied more than 70 new agents and conducted 100 cancer studies. Since 2015, HonorHealth Research Institute’s first-in-human clinical trials have been key to the FDA approval of at least two dozen new cancer treatments, including eight in 2019. These studies provide our community with early access to potential advances before they are available in routine practice.